Gradignan

Researchers are evaluating treatments for moderate acne in patients with darker skin types Fitzpatrick phototypes IV-VI, focusing on acne-related pigmentation that affects quality of life. This randomized controlled trial compares oral isotretinoin as a first-line treatment against the current standard of care involving oral antibiotics and topical creams. The study aims to assess which approach better improves pigmentation severity after six months. Participants will be assigned to one of two groups. One group receives oral isotretinoin starting at 0.5 mgkg daily for six months, with dose adjustments possible based on tolerance and effectiveness. The other group follows standard care, receiving topical tretinoin or adapalene along with doxycycline or lymecycline for three months, followed by evaluation at three and six months. Dose changes may occur according to clinical response. During the study, participants will attend monthly visits if receiving isotretinoin or visits at three and six months for the standard care group. Researchers will assess acne-related pigmentation severity, quality of life, and any adverse events. Participants must have a cell phone capable of taking high-definition selfies to assist in monitoring. The total study duration for each participant is six months, with ongoing safety and effectiveness checks.

This research aims to evaluate whether regular monitoring and feedback of symptoms can improve the quality of life for patients undergoing dialysis for end-stage renal disease ESRD. The study focuses on addressing the often overlooked symptoms that affect the physical and mental health quality of life in dialysis patients. It also assesses the feasibility and cost-effectiveness of electronically capturing patient-reported outcomes within a national dialysis registry. Participants are randomly assigned to either an experimental group or a control group. The experimental group completes symptom questionnaires every three months via a digital tablet during dialysis sessions, with severe symptoms automatically reported to healthcare teams for management. The control group receives usual care without systematic symptom monitoring. Both groups complete quality of life assessments every six months over 18 months. Half of the dialysis units have a clinical research nurse supporting data collection for 12 months, followed by local teams managing data collection for the remaining six months. During the study, patients provide symptom and quality of life data through digital questionnaires completed at regular intervals during dialysis. Researchers analyze these patient-reported outcomes, clinical data from the national registry, and healthcare usage from administrative databases. Interviews with patients and healthcare professionals explore the implementation process and perceptions of the intervention. The primary outcome is the physical health score from a validated kidney disease quality of life questionnaire after 12 months. The total participation and observation period lasts 18 months, with ongoing safety and data monitoring.